Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A gynecologic oncology group study

Journal of Clinical Oncology

Volumn 28, Issue 16, 2010, Pages 2727-2731

  Powell, Matthew A ^a   Filiaci, Virginia L ^a   Rose, Peter G ^a   Mannel, Robert S ^a   Hanjani, Parviz ^a   DeGeest, Koen ^a   Miller, Brigitte E ^a   Susumu, Nobuyuki ^a   Ueland, Frederick R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CANCER GROWTH; CANCER STAGING; CARCINOSARCOMA; CARDIOVASCULAR DISEASE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; ENDOCRINE DISEASE; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEMOLYSIS; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PAIN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; UTERINE CARCINOSARCOMA; VOMITING; AGED; CANCER INVASION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; HEALTH CARE QUALITY; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; UTERUS CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CARBOPLATIN; CARCINOSARCOMA; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PACLITAXEL; PROBABILITY; PROGNOSIS; PROGRAM EVALUATION; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 77954948152     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.8326     Document Type: Article

References (31)

1. Nielsen SN, Podratz KC, Scheithauer BW, et al: Clinicopathologic analysis of uterine malignant mixed Mullerian tumors. Gynecol Oncol 34:372-378, 1989 (Pubitemid 19218581)
2. Sartori E, Bazzurini L, Gadducci A, et al: Carcinosarcoma of the uterus: A clinicopathological multicenter CTF study. Gynecol Oncol 67:70-75, 1997 (Pubitemid 27433331)
3. Rose PG, Piver MS, Tsukada Y, et al: Patterns of metastasis in uterine sarcoma: An autopsy study. Cancer 63:935-938, 1989 (Pubitemid 19063205)
4. Sutton GP, Blessing JA, Rosenshein N, et al: Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol 161:309-312, 1989 (Pubitemid 19212192)
5. Sutton GP, Blessing JA, Photopulos G, et al: Gynecologic Oncology Group experience with ifosfamide. Semin Oncol 17:6-10, 1990 (suppl 4) (Pubitemid 20176942)
6. Thigpen JT, Blessing JA, Orr JW Jr, et al: Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: A Gynecologic Oncology Group Study. Cancer Treat Rep 70:271-274, 1986 (Pubitemid 16166174)
7. Gershenson DM, Kavanagh JJ, Copeland LJ, et al: Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol 5:618-621, 1987 (Pubitemid 17062500)
8. Curtin JP, Blessing JA, Soper JT, et al: Paclitaxel in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 83:268-270, 2001 (Pubitemid 33033064)
9. Muss HB, Bundy B, DiSaia PJ, et al: Treatment of recurrent or advanced uterine sarcoma: A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 55:1648-1653, 1985 (Pubitemid 15103908)
10. Omura GA, Blessing JA, Major F, et al: A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: A Gynecologic Oncology Group Study. J Clin Oncol 3:1240-1245, 1985 (Pubitemid 15226529)
11. Sutton G, Brunetto VL, Kilgore L, et al: A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol 79:147-153, 2000
12. Homesley HD, Filiaci V, Markman M, et al: Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: A Gynecologic Oncology Group Study. J Clin Oncol 25:526-531, 2007 (Pubitemid 350002959)
13. Toyoshima M, Akahira J, Matsunaga G, et al: Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol 94:774-778, 2004 (Pubitemid 39194474)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989 (Pubitemid 19272848)
16. Jelliffe R: Creatinine clearance: Bedside estimate. Ann Intern Med 79:604-605, 1973
17. Chen TT, Ng T: Optimal flexible designs in phase II clinical trials. Stat Med 17:2301-2312, 1998 (Pubitemid 28482675)
18. Atkinson EN, Brown BW: Confidence limits for probability of response in multistage phase II clinical trials. Biometrics 41:741-744, 1985
19. Silverberg SG, Major FJ, Blessing JA, et al: Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 9:1-19, 1990 (Pubitemid 20067452)
20. Major FJ, Blessing JA, Silverberg SG, et al: Prognostic factors in early-stage uterine sarcoma: A Gynecologic Oncology Group study. Cancer 71:1702-1709, 1993 (Pubitemid 23056094)
21. Wolfson AH, Brady MF, Rocereto T, et al: A Gynecologic Oncology Group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as postsurgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 107:177-185, 2007 (Pubitemid 47575740)
22. Thigpen JT, Blessing JA, Homesley HD, et al: Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma: A Gynecologic Oncology Group study. Am J Clin Oncol 8:350-352, 1985 (Pubitemid 16197682)
23. Slayton RE, Blessing JA, DiSaia PJ, et al: Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: A Gynecologic Oncology Group study. Cancer Treat Rep 71:661-662, 1987 (Pubitemid 17090275)
24. Muss HB, Bundy BN, Adcock L, et al: Mitoxantrone in the treatment of advanced uterine sarcoma: A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 13:32-34, 1990 (Pubitemid 20114555)
25. Slayton RE, Blessing JA, Clarke-Pearson D: A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus: A Gynecologic Oncology Group study. Invest New Drugs 9:93-94, 1991
26. Thigpen JT, Blessing JA, Beecham J, et al: Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: A Gynecologic Oncology Group study. J Clin Oncol 9:1962-1966, 1991
27. Fowler JM, Blessing JA, Burger RA, et al: Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 85:311-314, 2002 (Pubitemid 34522991)
28. Asbury R, Blessing JA, Podczaski E, et al: A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: A Gynecologic Oncology Group study. Am J Clin Oncol 21:306-307, 1998 (Pubitemid 28280148)
29. Asbury R, Blessing JA, Moore D: A phase II trial of aminothiadiazole in patients with mixed mesodermal tumors of the uterine corpus: A Gynecologic Oncology Group study. Am J Clin Oncol 19:400-402, 1996 (Pubitemid 26242241)
30. Ramondetta LM, Lacour RA, Euscher ED, et al: A phase II multicenter trial of paclitaxel and carboplatin in women with advanced or recurrent malignant mixed müllerian tumors (MMMT) of the uterus. J Clin Oncol 25:296s, 2007 (suppl; abstr 5589)
31. Hoskins PJ, Le N, Ellard S, et al: Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors: The British Columbia Cancer Agency experience. Gynecol Oncol 108:58-62, 2008 (Pubitemid 350299420)